SpringWorks Therapeutics, Inc. reported a net loss of $83.187 million for the three months ended March 31, 2025, an improvement from the $87.385 million net loss in the same period last year. The company's total revenue significantly increased to $49.087 million, up 134% from $21.006 million in Q1 2024, primarily driven by sales of OGSIVEO and GOMEKLI. Operating costs and expenses also rose, but the increase in revenue led to a reduced operating loss.

SpringWorks Therapeutics reported strong revenue growth from OGSIVEO, achieving $61.5 million in net product revenue for Q4 2024. The company also received FDA approval for GOMEKLI and ended the year with $461.9 million in cash and equivalents. However, it reported a net loss of $77.3 million for the quarter.

SpringWorks Therapeutics reported $49.3 million in OGSIVEO net product revenue for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities were $498.1 million as of September 30, 2024, which is expected to fund the company through profitability, anticipated in the first half of 2026.

SpringWorks Therapeutics reported a net product revenue of $40.2 million for OGSIVEO in the second quarter of 2024. The company completed the submission of its NDA for mirdametinib in NF1-PN. They also initiated a Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors.

SpringWorks Therapeutics reported a strong start to the OGSIVEO launch with $21.0 million in net product revenue for the first quarter of 2024. They also initiated the rolling NDA submission for mirdametinib in children and adults with NF1-PN.

SpringWorks Therapeutics reported $5.4 million in OGSIVEO net product revenue in the first partial quarter of launch, submitted a Marketing Authorization Application to the European Medicines Agency for nirogacestat, presented positive topline data from the Phase 2b ReNeu trial of mirdametinib, and ended 2023 with $662.6 million in cash, cash equivalents and marketable securities.

SpringWorks Therapeutics reported a net loss of $79.4 million, or $1.27 per share, for the third quarter of 2023. The company's cash, cash equivalents and marketable securities were $422.4 million as of September 30, 2023. They are on track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarter of 2023.

SpringWorks Therapeutics reported a net loss of $77.9 million for the second quarter of 2023. The company is preparing for the potential FDA approval of nirogacestat and anticipates topline data from the ReNeu trial in the fourth quarter.

SpringWorks Therapeutics reported its Q1 2023 financial results, highlighting the FDA's acceptance of the NDA for nirogacestat with Priority Review and the publication of the Phase 3 DeFi trial in the New England Journal of Medicine. The company is preparing for the potential launch of nirogacestat and advancing its pipeline, including the Phase 2b ReNeu trial for mirdametinib.

SpringWorks Therapeutics reported positive data from their Phase 3 DeFi trial of nirogacestat in desmoid tumors, which led to the FDA accepting their New Drug Application and granting Priority Review. They are also encouraged by the potential for mirdametinib as a therapy for children and adults with NF1-PN.

SpringWorks Therapeutics presented positive data from its Phase 3 DeFi trial of nirogacestat, expanded collaboration with GSK, and initiated a new Phase 2 trial of nirogacestat. They also strengthened their financial position, providing sufficient runway into 2026.

SpringWorks Therapeutics reported positive data from the Phase 3 DeFi trial and encouraging preliminary data from the study evaluating nirogacestat with low-dose belantamab mafodotin in patients with multiple myeloma. The company is focused on preparing for its first potential product launch and advancing its diversified targeted oncology pipeline.

SpringWorks Therapeutics reported a net loss of $61.8 million, or $1.26 per share, for the first quarter of 2022. The company continued to advance its diversified targeted oncology pipeline and expects to announce topline data from its Phase 3 DeFi study in the second quarter of 2022.

SpringWorks Therapeutics reported no revenue for Q4 2021. R&D expenses were $29.3 million, and G&A expenses were $26.5 million. The company reported a net loss of $56.1 million, or $1.15 per share. Cash, cash equivalents, and marketable securities were $432.7 million as of December 31, 2021.

SpringWorks Therapeutics reported a net loss of $41.0 million, or $0.84 per share, for the third quarter of 2021. As of September 30, 2021, cash, cash equivalents and marketable securities were $480.6 million.

SpringWorks Therapeutics executed well in Q2 2021, advancing the nirogacestat strategy, extending mirdametinib patent protection, and expanding the oncology pipeline.

SpringWorks Therapeutics reported a net loss of $29.8 million, or $0.62 per share, for the first quarter of 2021. As of March 31, 2021, the company's cash, cash equivalents and marketable securities were $541.0 million.

SpringWorks Therapeutics reported Q4 2020 financial results, featuring $35.0 million in revenue from the Jazz Pharmaceuticals agreement. The company's R&D expenses were $15.3 million, and G&A expenses totaled $8.5 million. Net income for the quarter was $11.3 million, and cash, cash equivalents, and marketable securities amounted to $561.8 million.

SpringWorks Therapeutics reported its Q3 2020 financial results, highlighting the completion of enrollment in the Phase 3 DeFi trial, advancements in developing nirogacestat as a cornerstone of BCMA combination therapy, and the progression of trials in biomarker-defined metastatic solid tumors. The company also completed an asset purchase and exclusive license agreement of global rights to FAAH Inhibitor PF-04457845 to Jazz Pharmaceuticals, receiving $35 million upfront payment and potential future milestone payments of up to $375 Million, and raised $269.5 million in net proceeds through follow-on public offering.

SpringWorks Therapeutics reported a net loss of $19.9 million for the second quarter of 2020. The company completed enrollment in the Phase 3 DeFi trial of nirogacestat and initiated a Phase 1 trial evaluating nirogacestat in combination with a BCMA therapy. SpringWorks had $291.2 million in cash, cash equivalents, and marketable securities as of June 30, 2020.

SpringWorks Therapeutics reported a net loss of $15.3 million, or $0.37 per share, for the first quarter of 2020. The company's cash and cash equivalents were $311.1 million as of March 31, 2020. They also announced the issuance of a new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039 and signed a clinical collaboration with Allogene to evaluate Nirogacestat in combination with Allogeneic BCMA CAR T Cell Therapy.

SpringWorks Therapeutics reported a net loss of $16.2 million for the fourth quarter of 2019. The company's cash and cash equivalents totaled $327.7 million as of December 31, 2019. They initiated a Phase 1 clinical trial of BGB-3245 and entered into a clinical collaboration agreement with Allogene Therapeutics.